Peak Sales Forecaster

Peak Sales Forecaster — The Revenue Architect

Peak sales is the single most influential variable in biotech valuation. A 2x difference in peak sales estimate produces roughly a 2x difference in rNPV — making it more impactful than PoS adjustments in most cases. Yet most analysts build revenue models with unstated assumptions about market share and penetration speed. This skill makes every assumption explicit and benchmarked against launch analogs.

The fundamental equation is deceptively simple: Revenue = Patients x Share x Price x Compliance. The complexity lives in forecasting each variable over time and across geographies.

Uptake & peak-sales data: launch-curve archetypes, pricing-by-category, compliance rates, and verified peak-sales analogs (Keytruda, Humira) live in references/launch-analog-benchmarks.md; the erosion tail is in market-dynamics' launch-and-erosion-benchmarks.md.

How to Run

Input

Steps

Step 1 — Establish Patient Volume Trajectory

Import the treatable addressable population from patient-population-sizer. Model patient volume growth over the forecast period:

Step 2 — Model Market Penetration (S-Curve)

Drug uptake follows a logistic S-curve. Select a launch analog to calibrate the curve shape:

Penetration curve formula: Share(t) = Peak_Share / (1 + e^(-k * (t - t_midpoint)))

Key S-curve parameters:

• Slope (k): Steeper for breakthrough designations, strong KOL advocacy, simple dosing. Flatter for complex administration, payer pushback, safety monitoring requirements.
• Midpoint (t_mid): Earlier for high unmet need. Later for markets requiring formulary negotiations or real-world evidence.
• Plateau duration: Assume 2-4 years at peak before genericization or next-gen competition erodes share.

Step 3 — Set Pricing

Price by modality, therapeutic area, and geography using current market benchmarks:

Pricing adjustments:

• Net-to-gross: US payers negotiate 30-60% rebates on list price (higher for competitive classes). Use net price for revenue modeling.
• IRA impact: Medicare negotiation under the Inflation Reduction Act begins 9 years post-approval for small molecules, 13 years for biologics. Model 25-60% price reduction when applicable.
• Biosimilar erosion: Assume 40-80% price erosion over 3-5 years post-LOE for biologics.

Step 4 — Apply Compliance and Persistence

Not all patients who start therapy remain on treatment for the full year.

Formula: Effective treated patients = Starting patients x Compliance rate

Step 5 — Build 10-Year Revenue Curve

Assemble the annual revenue model:

Year [t] Revenue = Population(t) x Share(t) x Net_Price(t) x Compliance

Apply these temporal dynamics:

• Years 1-2: Launch ramp (S-curve early phase), limited geographic coverage
• Years 3-5: Rapid uptake, geographic expansion (EU5 launch Year 2-3, Japan Year 3-4)
• Years 5-7: Peak sales plateau; potential label expansions add new patient pools
• Years 7-10: Competitive erosion, potential LOE, IRA negotiation impact

Step 6 — Benchmark Against Peak Sales Analogs

Cross-check the forecast against real-world peak sales by therapeutic area:

If the forecast significantly exceeds the top analog, scrutinize assumptions. If far below the lowest analog in the category, consider whether the indication is too narrow.

Step 7 — Compile Forecast

Output

PEAK SALES FORECAST — [Asset Name]
Indication: [disease, line of therapy]
Geography: [markets]
Launch Year: [year]

REVENUE BUILD:
  Treatable population (Year 1):          [N] patients
  Peak market share:                      [X]%
  Time to peak share:                     [X] years
  US net price (annual):                  $[X]
  Compliance rate:                        [X]%
  
10-YEAR REVENUE CURVE ($M):
  Year 1:   $[X]    (launch)
  Year 2:   $[X]    (ramp)
  Year 3:   $[X]    (US peak + EU launch)
  Year 4:   $[X]
  Year 5:   $[X]    << PEAK SALES YEAR >>
  Year 6:   $[X]    (plateau)
  Year 7:   $[X]    (competitive erosion begins)
  Year 8:   $[X]
  Year 9:   $[X]    (IRA/LOE impact if applicable)
  Year 10:  $[X]

PEAK ANNUAL REVENUE:     $[X]M (Year [N])
CUMULATIVE 10-YR REVENUE: $[X]M

SENSITIVITY:
  Bull case (peak share +10%, price +20%):   $[X]M peak
  Base case:                                  $[X]M peak
  Bear case (peak share -10%, price -20%):   $[X]M peak

LAUNCH ANALOG: [drug name] — [rationale for selection]

KEY ASSUMPTIONS:
  1. [Patient volume assumption]
  2. [Pricing/reimbursement assumption]
  3. [Competitive timing assumption]

KEY RISKS TO FORECAST:
  1. [Competitive threat — specific drug/company]
  2. [Pricing risk — IRA, payer pushback, ICER review]
  3. [Market access risk — formulary restrictions, step edits]

Error Handling

Cross-Domain Connections

• Biotech-venture/patient-population-sizer: Provides the patient volume input (Step 1)
• Biotech-venture/cost-estimator: Development and launch costs offset against peak revenue in rNPV
• Biotech-venture/pos-calculator: Probability weighting applied to this revenue stream in rNPV
• Biotech-venture/competitive-intelligence: Competitive entrants directly impact market share assumptions
• Biotech-venture/deal-economics: Peak sales drives deal valuation and royalty economics